Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
Regeneron reported that its weight-loss drug halved muscle loss when combined with Novo Nordisk's semaglutide in a trial.
Regeneron
Biopharmaceutical company
Company Info
Recent News
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
US FDA approves Regeneron's rare bone disorder drug
US FDA approves Regeneron's rare bone disorder drug